caa a22 4500 465789404 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216932 doi (NATIONALLICENCE)springer-10.1007/BF00216932 Phase II trial of 4′ deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma [Elektronische Daten] An Illinois Cancer Council Study [Christopher Rose, Thomas Lad, Lary Kilton, Joel Schor, Steven Rosen, Arthur Rossof, Richard Blough, Carole Johnson] Summary: A phase II trial of 4′ Deoxydoxorubicin (DXDX) was conducted in unresectable previously untreated non-small cell lung cancer patients. DXDX was administered every 3 weeks by short intravenous infusion at a starting dose of 30 mg/m2, with dose escalation to 40 mg/m2 toxicity permitting. Four responses, all partial, were observed in 35 evaluable patients, for a response rate of 11% (95% confidence limits 3.2% and 26.7%). Myelosuppression was the dose-limiting toxicity. Cardiotoxicity was not seen. DXDX has minimal activity against non-small cell lung cancer as a single agent at the dosage used in this study. Kluwer Academic Publishers, 1990 deoxydoxorubicin (DXDX) nationallicence non-small cell carcinoma (NSCC) nationallicence phase II trials nationallicence Eastern Cooperative Oncology Group (ECOG) nationallicence Rose Christopher Medical Oncology Section, Department of Medicine, University of Illinois at Chicago, USA aut Lad Thomas Medical Oncology Section, Department of Medicine, University of Illinois at Chicago, USA aut Kilton Lary Good Shepherd Hospital, Barrington, Illinois aut Schor Joel Medical Oncology Section, Department of Medicine, University of Illinois at Chicago, USA aut Rosen Steven Northwestern University, Chicago aut Rossof Arthur Rush-Presbyterian-St. Luke's Medical Center, Chicago aut Blough Richard Illinois Cancer Council, Chicago, USA aut Johnson Carole Illinois Cancer Council, Chicago, USA aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 97-99 0167-6997 8:1<97 1990 8 10637 https://doi.org/10.1007/BF00216932 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216932 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rose Christopher Medical Oncology Section, Department of Medicine, University of Illinois at Chicago, USA aut NATIONALLICENCE 700 1- Lad Thomas Medical Oncology Section, Department of Medicine, University of Illinois at Chicago, USA aut NATIONALLICENCE 700 1- Kilton Lary Good Shepherd Hospital, Barrington, Illinois aut NATIONALLICENCE 700 1- Schor Joel Medical Oncology Section, Department of Medicine, University of Illinois at Chicago, USA aut NATIONALLICENCE 700 1- Rosen Steven Northwestern University, Chicago aut NATIONALLICENCE 700 1- Rossof Arthur Rush-Presbyterian-St. Luke's Medical Center, Chicago aut NATIONALLICENCE 700 1- Blough Richard Illinois Cancer Council, Chicago, USA aut NATIONALLICENCE 700 1- Johnson Carole Illinois Cancer Council, Chicago, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 97-99 0167-6997 8:1<97 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer